Current Opinion in Psychiatry
November 15, 2021
Jerome Sarris, Diego Pinzon Rubiano, Kimberley Day et al.
12 citations
Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent findings Serotonergic psychedelics have been found to modulate brain networks underlying various...
Frontiers in Psychology
November 11, 2021
Anne C Wagner
13 citations
MDMA's first identified potential as a therapeutic catalyst was for couple therapy. Early work in the 1970s and 1980s explored its potential amongst seasoned psychotherapists and their clients. With the completion of the first pilot trial of MDMA-assisted psychotherapy with couples for PTSD, and as the possibility of conducting MDMA-assisted psychotherapy trials expands due to new regulatory...
Eastern Journal of Psychiatry
October 29, 2021
Dhananjoy Shaw, Chitra Chand
1 citation
Review ARticle][12] Yoga is a nonpharmacological means to develop overall mental health by improving willpower, emotional control, and self-confidence and reducing perceived fatigue, stress, and lifestyle-related disorders due to stress such as diabetes mellitus, hypertension, obesity, and many more through mantras, meditation, pranayama, and asanas. 13,14Mindfulness is a technique to purposely...
Sexual & Relationship Therapy
October 20, 2021
Dee Dee Goldpaugh
22 citations
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, and substance use disorders. These medicines have also been used in sacred, ritual settings for, in some cases, centuries. Often referred to as entheogens (meaning “creating the divine within”), psychedelic plant medicines such as psilocybin...
Brain Sciences
October 20, 2021
Serena Scarpelli, Valentina Alfonsi, Maurizio Gorgoni et al.
23 citations
Recent literature shows that the Coronovirus-19 (COVID-19) pandemic has provoked significant changes in dreaming. The current study intends to provide an update about dream variable changes during the second wave of COVID-19. A total of 611 participants completed a web survey from December 2020 to January 2021. Statistical comparisons showed that subjects had lower dream-recall frequency,...
Frontiers in Psychiatry
October 4, 2021
Maxemiliano V. Vargas, Retsina Meyer, Arabo A. Avanes et al.
162 citations
Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse...
Journal of Psychedelic Studies
October 1, 2021
Alan K. Davis, Pratheek Mangini, Yitong Xin
10 citations
Abstract Trauma exposure across the lifespan produces risks for posttraumatic stress disorder (PTSD), depression, anxiety, as well as global disability in functioning. This retrospective clinical chart review is the first of its kind to assess the utility of sublingual ketamine-assisted body-centered psychotherapy in trauma-exposed patients in a real world clinic setting. De-identified clinical...
Frontiers in Neuroscience
September 20, 2021
Lauren Lepow, Hirofumi Morishita, Rachel Yehuda
70 citations
As psychedelic compounds gain traction in psychiatry, there is a need to consider the active mechanism to explain the effect observed in randomized clinical trials. Traditionally, biological psychiatry has asked how compounds affect the causal pathways of illness to reduce symptoms and therefore focus on analysis of the pharmacologic properties. In psychedelic-assisted psychotherapy (PAP),...
Frontiers in Psychiatry
September 6, 2021
Elena Argento, Devon Christie, Lindsay Mackay et al.
12 citations
The COVID-19 pandemic stands to have impacts on mental health and well-being that will extend beyond its formal resolution. Before COVID-19, mental health disorders were already challenging global healthcare systems, directly accounting for 7.4% of the total burden of disease (1, 2). An estimated 1 billion people worldwide suffer from a mental health disorder, with the two most common...
Journal of Psychopharmacology
August 31, 2021
Isaac Cohen, Laken Barber, Tyson Paul Dubnicka et al.
1 citation
3,4 Methylenedioxymethamphetamine (MDMA)-assisted therapy has been recently found to be highly effective for treatment of posttraumatic stress disorder (PTSD). Previous studies have been inconclusive in elucidating potential MDMA genotoxicity. We performed three regulatory compliant studies to investigate the potential of genotoxic effects of MDMA treatment in humans: (1) an in vitro bacterial...